Nicotinamide Riboside Patent Landscape
Identifiers
Which organizations and claims shape current development around Nicotinamide riboside?
Key organizations shaping current development include Chromadex Inc, which claims stabilized wax prill formulations and infant formula applications (AU2020224158B2, AU2022287565B2). Suntory Holdings Ltd claims NR/sesamin combinations for NAD+ maintenance (AU2021271500B2). Other active assignees include Amazentis SA (NR with urolithin A for mitochondrial function), Societe des Produits Nestle SA (NR with ketones for brain health), and Nippon Medical School Found (NR with uridine/inosine for ATP/NAD). Health And Happiness H&h Hong Kong Ltd claims anti-aging compositions with ergothioneine and PQQ. These claims focus on synergistic efficacy, stability, and targeted health outcomes.
How is Nicotinamide riboside innovation changing in Food & Beverage?
Monthly patent filings by domain
Which technical problems do recent patents address with Nicotinamide riboside?
Recent patents primarily address the technical problem of enhancing the bioavailability and efficacy of Nicotinamide riboside (NR) through stabilization and synergistic combinations. Specific technical challenges include improving stability via wax prill encapsulation (AU2020224158B2, NZ779753A) and creating novel salt forms like NR α-ketoglutarate (CN120365337A). Other patents focus on boosting NAD+ and ATP levels more effectively by combining NR with compounds such as sesamin, uridine, and inosine (AU2021271500B2, WO2026053929A1). A further problem is targeting specific physiological outcomes—mitochondrial function, brain energy status, and skin wrinkles—through tailored formulations (US12220424B2, US2025134918A1, KR102784901B1).
How do recent patents change the role or application of Nicotinamide riboside?
Recent patents expand NR's role from a general NAD+ precursor to a versatile active ingredient in specialized applications. It is now claimed for use in infant formula at specific dosages (AU2022287565B2), as an anti-wrinkle agent in cosmetics (KR102784901B1), and in combination with ketones for brain health and neurodegenerative conditions (US2025134918A1). The ingredient is also positioned as part of chronobiological systems, administered at specific times of day to modulate cellular metabolism (NL4001512A). This shift indicates a move from generic anti-aging supplements toward targeted, condition-specific products.
How is Nicotinamide riboside used in Food & Beverage patents?
Which Food & Beverage product categories feature Nicotinamide riboside in recent patents?
Which product categories and formulation strategies emerge in recent work on Nicotinamide riboside?
Emerging formulation strategies include synergistic combinations with polyphenols (sesamin, resveratrol) and mitochondrial support agents (CoQ10, urolithin A) to enhance anti-aging and energy-related efficacy (AU2021271500B2, NL4001512A, US12220424B2). Product categories span instant beverage powders with NR at 1.5-15 wt% (NL2039020B1), dietary supplements, and cosmetic compositions. A key strategy is stabilization: wax prills for edible compositions (AU2020224158B2) and novel salt forms like NR α-ketoglutarate (CN120365337A). Another approach is chronobiological delivery, with separate day and night compositions (NL4001512A).
Where is the evidence-backed white space for further development of Nicotinamide riboside?
Evidence-backed white space exists in the development of novel salt forms and derivatives of NR, as exemplified by the NR α-ketoglutarate patent (CN120365337A). This area appears less crowded than combination formulations. Another potential space is the integration of NR into chronobiological supplement systems, which is currently claimed by only one entity (NL4001512A). Additionally, while NR is claimed for infant formula and cosmetics, these applications are limited to a few patents, suggesting room for further exploration in these specialized domains.